Danaher Corporation has been the focus of various investment firms and analysts, indicating a generally positive sentiment despite some adjusting their price targets. The firm has strengthened its financial stability by securing a
$5 billion revolving credit facility. Meanwhile, various investment entities, including Mirae Asset Global Investments, Whittier Trust Co, and SeaBridge Investment Advisors, have grown their stake in Danaher. The company is gearing up to post
Q1 earnings and is expected to provide significant updates that can potentially affect the stock’s future performance. Notably, Danaher’s expanded
infectious disease partnership could significantly shape its recurring revenue. On a different note, some stakes have been sold by entities like Border to Coast Pensions and State of Alaska Department of Revenue. The corporation has seen an increase in its short interest and gave a consensus rating of 'Moderate Buy' by brokerages. The addition of Masimo in an all-cash deal aids Danaher's strategic positioning. Despite bumpy patches and lowered outlook for 2019, the company appears to be on a positive footing in the long-term view.
Biotech improvement adds a promising segment to its portfolio.
Danaher Corporation DHR News Analytics from Wed, 13 Aug 2025 07:00:00 GMT to Sat, 18 Apr 2026 18:50:18 GMT -
Rating 6
- Innovation -2
- Information 9
- Rumor 1
